HOME >> BIOLOGY >> NEWS
Study identifies which patients can benefit from targeted lung cancer drug and why

BOSTON In a study that stands to benefit thousands of patients with non-small cell lung cancer around the world, researchers at Dana-Farber Cancer Institute and in Japan have found that patients whose lung cancers harbor a malfunctioning version of a protein called EGFR respond dramatically to the drug gefitinib (IressaTM).

The findings are the first fruit of an approach that seeks a systematic route to the development of new cancer therapies. By scanning the DNA of cancer cells, Dana Farber scientists and colleagues at the Massachusetts Institute of Technology's Broad Institute are hunting for mutated genes that instruct cells to produce abnormal versions of growth proteins called tyrosine kinases. The hope is that drugs known to block such proteins can stymie cancer growth while leaving normal cells intact.

The study will be published this week in the online version of the journal Science (www.sciencemag.org). Related research from Massachusetts General Hospital Cancer Center, a member of the Dana-Farber/Harvard Cancer Center, will be concurrently released online by the New England Journal of Medicine on April 29.

"Imatinib (GleevecTM) [which has halted or shrunk tumors in patients with a form of leukemia and digestive-system tumor] is probably the best-known example of a drug that works by targeting a specific, mutated tyrosine kinase," says William Sellers, M.D., who is co-senior author of the study with his Dana-Farber colleagues Bruce Johnson, M.D., and Matthew Meyerson, M.D., Ph.D. "So far, though, this approach has been most notable in cancers that are relatively rare. Our study shows that it can be effective for a common form of cancer as well." Non-small cell lung cancer (NSCLC) accounts for about 85 percent of all cases of lung cancer, the number one cancer killer of both men and women in the United States.

The study's lead authors are J. Guillermo Paez, Ph.D., and Pasi Janne, M
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
29-Apr-2004


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... ... July 18, 2019 , ... Flagship Biosciences, the advanced ... to its executive team as Vice President of Operations. Ms. James brings a ... new role, Ms. James is responsible for ensuring on-time delivery of all projects ...
(Date:7/17/2019)... ... July 17, 2019 , ... ... acclaimed pediatric urologists are among the professionals honored in U.S. News & ... among the country’s pediatric healthcare landscape. , Georgia Urology’s wholly-owned subsidiary, ...
(Date:7/17/2019)... ... 15, 2019 , ... RCH Solutions (RCH), a ... companies, announces the availability of new specialty advisory practice, a Public Cloud Managed ... emerging bio-pharma companies interested in achieving specific outcomes related to public Cloud adoption. ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, the leader ... leader in opioid treatment, announced today they are partnering to combat the opioid ... deployed its virtual care platform at the Mayo Clinic to drive shared decision ...
(Date:6/11/2019)... ... June 11, 2019 , ... A study released today in ... are able to incorporate into human CD34+ cells, modifying their gene expression and ... increased the cells’ ability to lodge into bone marrow. This research performed by ...
(Date:5/31/2019)... ... 29, 2019 , ... For many years, the primary forms of cancer treatment ... therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T ... cell receptors known as “CARs”. The CAR enables the final product to produce chemicals ...
(Date:5/31/2019)... , ... May 30, 2019 , ... ... thinking on Data Integrity on July 08-09, 2019 in Boston, MA. This peer ... and medical device organizations. , The training will kick off with a compendial ...
Breaking Biology Technology:
Cached News: